Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARC101 |
Synonyms | |
Therapy Description |
Limited information is currently available on ARC101, a putative bispecific T-cell engager targeting CLDN6 and CD3 (Mar 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARC101 | ARC 101|ARC-101 | CD3 Antibody 107 CLDN6 Antibody 10 | Limited information is currently available on ARC101, a putative bispecific T-cell engager targeting CLDN6 and CD3 (Mar 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06672185 | Phase I | ARC101 | ARC101 in Advanced Solid Tumors | Recruiting | AUS | 0 |